US-based pharmaceutical company Merck’s Global Health Innovation Fund has gained another $250m to invest in healthcare and will look outside of the US for the next tranche.
The additional commitment comes after the corporate venturing group has invested nearly all of its first tranche within the past two years in healthcare start-ups outside Merck’s core sectors of pharmaceuticals, vaccines, consumer products and animal health businesses.
William Taranto, managing director of Merck’s Global Health Innovation Fund (pictured), said: “We have deployed…
